Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
41 patients with ES-SCLC, 65.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
Our results showed a statistically significant longer PFS in patients with ES-SCLC and high percentages of circulating PD-L1 monocytes.
[INTRODUCTION] Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small cell lung cancer (ES-SCLC), long-term survival remains
- 95% CI 4.65 to 7.28
APA
Piedra A, Guinart-Cuadra A, et al. (2026). Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).. Journal of translational medicine, 24(1). https://doi.org/10.1186/s12967-026-07896-7
MLA
Piedra A, et al.. "Baseline PD-L1 expression on circulating immune cells as a predictor of survival and immune-related adverse events in extensive-stage small-cell lung cancer patients treated with durvalumab and carboplatin-etoposide (NCT04712903 Trial).." Journal of translational medicine, vol. 24, no. 1, 2026.
PMID
41764558 ↗
Abstract 한글 요약
[INTRODUCTION] Despite improved efficacy with first-line immune checkpoint inhibitors plus platinum-based chemotherapy for extensive-stage small cell lung cancer (ES-SCLC), long-term survival remains limited. There is currently no available predictive biomarker to identify which patients would benefit most from this treatment. We hypothesized that pre-treatment PD-L1 expression on circulating immune cells might predict survival outcomes and toxicity.
[MATERIAL AND METHODS] This prospective, multi-center observational study included patients with untreated ES-SCLC treated with first-line durvalumab plus platinum-based chemotherapy. The percentages of circulating PD-L1 immune cells at baseline were analysed by flow cytometry to assess their association with survival outcomes and the development of immune-related adverse events (irAEs).
[RESULTS] Among 41 patients with ES-SCLC, 65.9% were male, 73.2% had an ECOG-PS 1, 9.8% had central nervous system (CNS) metastases and 31.7% had liver metastases. Sixteen patients (39%) experienced irAEs. Median PFS was longer in patients with high percentages of circulating PD-L1 monocytes compared to those with low percentages: 8.97 months (95% CI NR to NR) vs. 5.97 months (95% CI 4.65 to 7.28), = 0.007. There was a trend toward longer median OS in patients with ES-SCLC and high percentages of circulating PD-L1 monocytes versus low percentages: NR (95% CI NR-NR) vs. 9.13 months (95% CI 6.34 to 11.92), = 0.092. Patients with higher circulating PD-L1 neutrophils correlated with the development of irAES ( = 0.007).
[CONCLUSIONS] Our results showed a statistically significant longer PFS in patients with ES-SCLC and high percentages of circulating PD-L1 monocytes. This suggests PD-L1 expression on monocytes might be established as a predictive biomarker for patients with ES-SCLC treated with upfront chemo-immunotherapy.
[TRIAL REGISTRATION] NCT04712903 Trial. Last registered 1 December 2025, https://www.clinicaltrials.gov/study/NCT04712903.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12967-026-07896-7.
[MATERIAL AND METHODS] This prospective, multi-center observational study included patients with untreated ES-SCLC treated with first-line durvalumab plus platinum-based chemotherapy. The percentages of circulating PD-L1 immune cells at baseline were analysed by flow cytometry to assess their association with survival outcomes and the development of immune-related adverse events (irAEs).
[RESULTS] Among 41 patients with ES-SCLC, 65.9% were male, 73.2% had an ECOG-PS 1, 9.8% had central nervous system (CNS) metastases and 31.7% had liver metastases. Sixteen patients (39%) experienced irAEs. Median PFS was longer in patients with high percentages of circulating PD-L1 monocytes compared to those with low percentages: 8.97 months (95% CI NR to NR) vs. 5.97 months (95% CI 4.65 to 7.28), = 0.007. There was a trend toward longer median OS in patients with ES-SCLC and high percentages of circulating PD-L1 monocytes versus low percentages: NR (95% CI NR-NR) vs. 9.13 months (95% CI 6.34 to 11.92), = 0.092. Patients with higher circulating PD-L1 neutrophils correlated with the development of irAES ( = 0.007).
[CONCLUSIONS] Our results showed a statistically significant longer PFS in patients with ES-SCLC and high percentages of circulating PD-L1 monocytes. This suggests PD-L1 expression on monocytes might be established as a predictive biomarker for patients with ES-SCLC treated with upfront chemo-immunotherapy.
[TRIAL REGISTRATION] NCT04712903 Trial. Last registered 1 December 2025, https://www.clinicaltrials.gov/study/NCT04712903.
[SUPPLEMENTARY INFORMATION] The online version contains supplementary material available at 10.1186/s12967-026-07896-7.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Liquid biopsy reveals the immune status and protein profiles linked to CTC burden and clinical outcomes in metastatic breast cancer.
- Immune cell changes following chemotherapy in advanced pancreatic cancer with variations based on gender.
- The effect of circulating CD4+ and CD8+ T cells on the prognosis in advanced postoperative pancreatic adenocarcinoma patients who received chemotherapy.
- The CDK inhibitor Roscovitine enhances the therapeutic efficacy of anti-PD-1 in non-small cell lung cancer.